Small molecule-based PD-1 pathway blockade for Human cancer therapy: Lovastatin (brand name: Mevacor), a hypolipidemic agent, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 8/January/2017, 10.46 pm

Molecular therapy for triple-negative breast tumors: Lovastatin (brand name: Mevacor), a statin drug used in the treatment of hypercholesterolemia, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 8/January/2017, 9.54 pm
January 8, 2017
Molecular therapy for Myocardial Infarction: Simvastatin (brand name: Zocor), a lipid-lowering medication, inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 8/January/2017, 11.26 pm
January 8, 2017
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapy: Lovastatin (brand name: Mevacor),  a hypolipidemic agent, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year a few years ago.


From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people globally are diagnosed with cancer, and a little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to prevent an individual from being susceptible to cancer by strengthening his/her own immune system; (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and prevent metastatic progression and relapse of cancers.


Research Findings

This study suggests a small molecule-based Human cancer immunotherapy. Lovastatin (brand name: Mevacor),  a statin drug used in the treatment of hypercholesterolemia, has been shown to function as an anticancer agent in a number of cancers, including Triple-negative breast cancer (TNBC). However, the detailed mechanism of action is yet to emerge.

price-50[easy_payment currency=”USD”]

The study presented here suggests that, Lovastatin, by decreasing the activity of its target gene, it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing “Lovastatin or its analogues or Lovastatin plus any of the known anti-cancer agents” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed mechanistic information: How Lovastatin suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation


References:

Citation: Boominathan, L., Small molecule-based PD-1 pathway blockade for Human cancer therapy: Lovastatin (brand name: Mevacor),  a hypolipidemic agent, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 8/January/2017, 10.46 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.